AASLD Hot Updates on MASLD from the 2023 Annual Meeting
Editor's Note: On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on…
Dr. Alexander Fosså：Phase II waveLINE-004 Study of ROR1-ADC Treatment for R/R DLBCL
On the 17th International Conference on Malignant Lymphoma (ICML), Dr. Alexander Fosså from Oslo University Hospital presented the results of the Zilovertamab vedotin (MK-2140) treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), a Phase II open-label, waveLINE-004 study. Oncology Frontier interviewed Dr. Fosså at the conference.